Influence of indocyanine green on plasma disappearance and biliary excretion of a synthetic thrombin inhibitor of the 3-amidinophenylalanine piperazide-type in rats

Pharmaceutical Research

Volumn 15, Issue 5, 1998, Pages 751-754

  Hauptmann, Jörg ^a   Stürzebecher, Jörg ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Bile; Indocyanine green; Plasma; Rats; Thrombin inhibitor

Indexed keywords

ICG PULSION; INDOCYANINE GREEN; NALPHA (2 NAPHTHYLSULFONYL) 3 AMIDINOPHENYLALANINE CARBOXYMETHYLPIPERAZIDE; PEFA 1023; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; FIRST PASS EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; THROMBIN TIME;

ANALYSIS OF VARIANCE; ANIMALS; BILE; COLORING AGENTS; FEMALE; INDOCYANINE GREEN; METABOLIC CLEARANCE RATE; MOLECULAR MIMICRY; PIPERIDINES; RATS; RATS, WISTAR; THROMBIN;

EID: 0031779869     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011927204847     Document Type: Article

References (19)

1. J. Hauptmann and F. Markwardt. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin. Thrombos. Hemostas. 18:200-217 (1992).
2. S. D. Kimball. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coag. & Fibrinol. 6:511-519 (1995).
3. J. Hauptmann, F. Markwardt, and M. Richter. Tierexperimentelle Untersuchungen zur Pharmakokinetik von Nα-Tosyl-3-amidino-phenylalaninpiperidid (TAPAP), einem neuen Thrombininhibitor. Pharmazie 37:430-433 (1982).
4. B. Kaiser, J. Hauptmann, A. Weiss, and F. Markwardt. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed. Biochim. Acta 44:1201-1210 (1985).
5. J. Hauptmann, B. Kaiser, M. Paintz, and F. Markwardt. Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rabbits and rats. Biomed. Biochim. Acta 46:445-453 (1987).
6. L. R. Bush. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev. 9:247-263 (1991).
7. G. F. Smith, D. Gifford-Moore, T. J. Craft, N. Chirgadze, K. J. Ruterbories, T. D. Lindstrom, and J. H. Satterwhite. Efegatran: A new cardiovascular anticoagulant. In R. Pifarre (ed.), New Anticoagulants for the Cardiovascular Patient, Hanley & Belfus, Philadelphia, 1997, pp 265-300.
8. H. Bounameaux, H. Ehringer, J. Hulting, H. Rasche, H. J. Rapold, and M. Zultak, and the ADVENT investigators. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Results of the European multicenter ADVENT trial. Thromb. Haemost. 78:997-1002 (1997).
9. J. Hauptmann and B. Kaiser. In vitro and in vivo comparison of arginine- and benzamidine-derived highly potent synthetic thrombin inhibitors. Pharmazie 46:57-58 (1991).
10. U. Eckhardt, W. Stüber, G. Dickneite, M. Reers, and E. Petzinger. First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Biochem. Pharmacol. 52:85-96 (1996).
11. U. Eckhardt, J. A. Horz, E. Petzinger, W. Stüber, M. Reers, G. Dickneite, H. Daniel, M. Wagener, B. Hagenbuch, B. Stieger, and P. J. Meier. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology 24:380-384 (1996).
12. J. H. Lin, I.-W. Chen, K. J. Vastag, and D. Ostovic. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:730-735 (1995).
13. J. Stürzebecher, D. Prasa, J. Hauptmann, P. Wikström, and H. Vieweg. Synthesis and structure-activity relationship of potent thrombin inhibitors: Piperazides of 3-amidinopenylalanine. J. Med. Chem. 40:3091-3099 (1997).
14. C. D. Klaassen. Effects of phenobarbital on the plasma disappearance and biliary excretion of drugs in rats. J. Pharmacol. Exp. Ther. 175:289-300 (1970).
15. J. Hauptmann, F. Etemad. K. Ziegler, J. Stürzebecher, and E. Petzinger. Uptake in rat hepatocytes and hepatic clearance in vivo of cationic amidinophenylalanine-derived peptidomimetic thrombin inhibitors. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:Suppl., R 8 (1997) (Abstr.).
16. E. Petzinger. Transport of organic anions in the liver. Rev. Physiol. Biochem. Pharmacol. 123:49-211 (1994).
17. T. Iga and C. D. Klaassen. Hepatic extraction of nonmetabolizable xenobiotics in rats. J. Pharmacol. Exp. Ther. 211:690-697 (1979).
18. B. Hagenbuch. Molecular properties of hepatic uptake systems for bile acids and organic anions. J. Membrane Biol. 160:1-8 (1997).
19. J. Hursting, J. C. Becker, J. L. Joffrion, G. D. Knappenberger, and R. P. Schwarz. Effect of hepatic function on the pharmacokinetics and pharmacodynamics of argatroban. Thromb. Haemostas. Suppl. 1997:483 (1997) (Abstr.).